EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation

Tirzah Braz Petta iD, Joseph Carlson

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms251910427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Tirzah Braz Petta und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Drug Resistance, Neoplasm, Poly(ADP-ribose) Polymerase Inhibitors, BRCA1 Protein. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CNPq/Brazil, CancerFonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 50% of patients diagnosed with ovarian cancer harbor tumors with mutations in BRCA1, BRCA2, or other genes involved in homologous recombination repair (HR). The presence of homologous recombination deficiency (HRD) is an approved biomarker for poly-ADP-ribose polymerase inhibitors (PARPis) as a maintenance treatment following a positive response to initial platinum-based chemotherapy. Despite this treatment option, the development of resistance to PARPis is common among recurrent disease patients, leading to a poor prognosis. In this study, we conducted a comprehensive analysis using publicly available datasets to elucidate the molecular mechanisms driving PARPi resistance in BRCA1-deficient ovarian cancer. Our findings reveal a central role for the interferon (IFN) pathway in mediating resistance in the context of BRCA1 deficiency. Through integrative bioinformatics approaches, we identified LY6E, an interferon-stimulated gene, as a key mediator of PARPi resistance, with its expression linked to an immunosuppressive tumor microenvironment (TME) encouraging tumor progression and invasion. LY6E amplification correlates with poor prognosis and increased expression of immune-related gene signatures, which is predictive of immunotherapy response. Interestingly, LY6E expression upon PARPi treatment resistance was found to be dependent on BRCA1 status. Gene expression analysis in the Orien/cBioPortal database revealed an association between LY6E and genes involved in DNA repair, such as Rad21 and PUF60, emphasizing the interplay between DNA repair pathways and immune modulation. Moreover, PUF60, Rad21, and LY6E are located on chromosome 8q24, a locus often amplified and associated with the progression of ovarian cancer. Overall, our study provides novel insights into the molecular determinants of PARPi resistance and highlights LY6E as a promising prognostic biomarker in the management of HRD ovarian cancer. Future studies are needed to fully elucidate the molecular mechanisms underlying the role of LY6E in PARPi resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsDrug Resistance, NeoplasmPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinFemaleHumansImmunomodulationTumor MicroenvironmentAntigens, LyGene Expression Regulation, NeoplasticInterferonsPrognosisBiomarkers, Tumor

Stichwörter der Autor:innen

cellular immunityhumaninterferonlocus Elymphocyte antigen 6 complexovarian neoplasmspoly(ADP-ribose) polymerase inhibitors

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBRCA1 protein, humanAntigens, LyInterferonsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
  • Centro de Biociencias, Departmento de Biologia Celular e Genetica, Universidade Federal do Rio Grande do Norte, Natal CEP 59078-970, Brazil.
  • Department of Pathology, City of Hope, Duarte, CA 91010, USA.

ORCID-Profile: Tirzah Braz Petta

Förderung

  • CNPq/Brazil
  • CancerFonden

Zitieren

APA

Petta, T. B., & Carlson, J. (2024). Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910427

Vancouver

Petta TB, Carlson J. Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910427

BibTeX
@article{Petta2024,
  author = {Petta, Tirzah Braz and Carlson, Joseph},
  title = {Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms251910427}
}
Kostenlos starten →